#Astellas Pharma (ALPMY)

Astellas Pharma Inc Announcement Tokyo, Oct. 18, 2024, Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, Astellas) announced that the United States FDA has approved VYLOY (zolbetu...

Prohost Letter #457 Discovering The Root Causes of Diseases   Biotech firms with solid scientific fundamentals are racing towards unveiling the root-causes of various diseases that have yet to be comp...

Seagen, Astellas Pharma & Merck Collaboration Seagen ( SGEN ) and Astellas Pharma ( ALPMY ) have entered a clinical collaboration agreement with Merck to evaluate the combination of Seagen’s and Astel...

Recent Gene Therapy News On August 20, 2020 Audentes Therapeutics , which was taken over by Astellas ( ALPMY ) for over $3 billion, announced that a third patient has passed away in a clinical trial e...

CytomX Therapeutics CytomX ( CTMX ) is a clinical-stage oncology-focused biopharmaceutical company developing a novel class of investigational antibody therapeutics based on the firm’s Probody® techno...

Prohost Letter #432 The ASCO 2019 Special Edition SPRAYING FEAR The Victims Are The most disturbed victim of the instigated and irrelevant fear against investing in the stock market is the market itse...